It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Work from home jobs offer flexibility and extra cash to help pay off debt. Explore opportunities that fit your schedule.
25,050 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
As AI demand soars, Micron sits at the center of memory hardware used in data centers. This article breaks down wheth...
Inflation isn’t just a headline—it's a real market force that tests how consumers spend on discretionary goods. Explo...
Cyclops, a Miami-based payments infrastructure startup, closed a $20 million Series A to accelerate settlement speeds...
A midrange, budget-friendly Apple device could broaden the company’s market and boost services revenue. This guide an...
The SPCX IPO surged on debut, lifting sentiment across equities. Investors are eyeing non-SPCX opportunities as the m...
MercadoLibre fell in February amid margin concerns and tougher competition in LATAM. This article breaks down the for...
A $1 million portfolio can drain quickly once taxes and withdrawal rules bite. Experts warn that counting gross yield...
Microsoft marks 40 years since its 1986 IPO, a milestone that underscores the power of long-term investing. The anniv...
A high-ranking Google DeepMind AI executive leaves for OpenAI, triggering investor chatter about Alphabet stock and t...
Alibaba shares slid about 7% after quarterly results, underscoring a push into AI and cloud infrastructure. Investors...
A prominent analyst argues SpaceX could surge, but practical hurdles and private-market realities temper the enthusia...